Abstract
Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be lifethreatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor κ B (NFκB) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NFκB activation itself, or the production of cytokines that stimulate NFκB, such as tumor necrosis factor (TNF) α. To date there have been few tests of drugs that are specific inhibitors of the NFκB / TNFα axis. However preliminary results in animal models are encouraging and go some way in establishing the NFκB cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.
Keywords: p38 MAPK inhibitors, COX 2, nuclear peroxisome proliferator activated receptor, nerve conduction velocity, I kappa B kinase 2
Current Drug Targets
Title: Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Volume: 9 Issue: 1
Author(s): Norman E. Cameron and Mary A. Cotter
Affiliation:
Keywords: p38 MAPK inhibitors, COX 2, nuclear peroxisome proliferator activated receptor, nerve conduction velocity, I kappa B kinase 2
Abstract: Neuropathy is a common complication of diabetes mellitus, which reduces the quality of life and may be lifethreatening. The etiology is complex and multifactorial: hyperglycemia and dyslipidemia give rise to oxidative stress and formation of advanced glycation and lipoxidation end products. These stimulate inflammatory processes, nuclear factor κ B (NFκB) activation being of central importance. Many of the drugs that have been developed for treatment of diabetic complication at least in part work through suppressing either NFκB activation itself, or the production of cytokines that stimulate NFκB, such as tumor necrosis factor (TNF) α. To date there have been few tests of drugs that are specific inhibitors of the NFκB / TNFα axis. However preliminary results in animal models are encouraging and go some way in establishing the NFκB cascade as an important therapeutic target for diabetic vascular complications in general, and neuropathy in particular.
Export Options
About this article
Cite this article as:
Cameron E. Norman and Cotter A. Mary, Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway, Current Drug Targets 2008; 9 (1) . https://dx.doi.org/10.2174/138945008783431718
DOI https://dx.doi.org/10.2174/138945008783431718 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design The Diabetic Charcot Foot
Current Diabetes Reviews Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Recent Progress in the Development of Selective TRPV1 Antagonists for Pain
Current Topics in Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview
Current Diabetes Reviews Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews A Review on Different Analytical Techniques for Determination of DNP Drugs and their Metabolites in Pharmaceutical Formulations
Current Pharmaceutical Analysis Metabolic Therapy of Heart Failure
Current Pharmaceutical Design